After Pfizer, Serum Institute of India Applies for Use of COVID-19 Vaccine in India
At a time when UK is all set to administer Pfizer Inc.’s COVID-19 vaccine while the US regulator, in all likelihood, could approve the Pfizer vaccine, Serum Institute of India (SII), has sought emergency use authorization (EUA) in the country for AstraZeneca Plc’s COVID-19 vaccine candidate.
The world’s largest vaccine producer by volume, SII Chief Executive Officer Adar Poonawala tweeted on Monday, December 7 “As promised, before the end of 2020
, @SerumInstIndia has applied for emergency use authorisation for the first made-in-India vaccine, COVISHIELD. This will save countless lives…”.
According to the Indian Council of Medical Research (ICMR), the SII has already manufactured 40 million doses of the vaccine under the at-risk manufacturing and stockpiling license it obtained from the Drugs Controller General of India (DGCI). India is the second most affected country by the virus.
India's Covid-19 tally stands at 96,74,378, and death toll climbed to 1,40,505. Total discharged cases is at 91,00,792. The virus has globally claimed over 1.5 million lives.
- India News
- COVID vaccine
- Serum Institute of India
- COVID-19 Vaccine in India